

EIP-1036

Revision 4

Date of issue: 03.05.2024

# Nitrosamines

EMA/369136/2020; FDA Guidance for Industry "Control of Nitrosamine Impurities in Human Drugs" **MEGGLE Products:** 

- Lactose Monohydrate: CapsuLac<sup>®</sup> 60, GranuLac<sup>®</sup> 70, GranuLac<sup>®</sup> 70 MS, GranuLac<sup>®</sup> 80, GranuLac<sup>®</sup> 140, GranuLac<sup>®</sup> 140 S, GranuLac® 200, GranuLac® 200 MS, GranuLac® 200 S, GranuLac® 230, InhaLac® 70, InhaLac® 120, InhaLac® 140, InhaLac® 145, InhaLac® 150, InhaLac® 160, InhaLac® 180, InhaLac® 230, InhaLac® 251, InhaLac® 300, InhaLac® 400, InhaLac® 500, Lactose Monohydrate 200 Mesh IP, Lactose Monohydrate Impalpable, Lactose Monohydrate Low Endotoxin, PrismaLac® 40, SacheLac® 80, SorboLac® 400, SpheroLac® 100, Tablettose® 70, Tablettose® 80, Tablettose® 100, Tablettose® 100 MS

The formation of potent genotoxic nitrosamines as impurities is possible in the presence of secondary, tertiary, or quaternary amines and nitrite salts under acidic reaction conditions.

Regarding the requests of EMA-CHMP and FDA-CDER that marketing authorisation holders for human medicines containing chemically synthesised active substances have to evaluate the risk for the possible presence of nitrosamines (e.g. NDMA, NDEA, NMBA, NMPA, NIPEA, NDIPA), a risk evaluation was conducted for the MEGGLE Products used as excipients to support the marketing authorisation holders. This evaluation is based on the IPEC Questionnaire and attached.

The risk evaluation reflects the whole manufacturing process at MEGGLE starting with whey independent from the defined starting material as regard of GMP requirements.

Whey does not contain relevant amounts of nitrates (as precursor of nitrites) and nitrites. Testing on nitrates and nitrites is conducted as part of incoming goods inspection. The acceptance limits are as follows: Nitrate < 50 ppm, Nitrite < 5 ppm.

The MEGGLE Products are not chemically synthesised. Organic solvents, catalysts and other reagents which might be a reason for the presence of secondary, tertiary, or quaternary amines and nitrite salts are not used. Furthermore, strongly acidic conditions as necessary prerequisite for the formation of nitrosamines are not achieved during manufacturing process.

MEGGLE lactose monohydrate products are tested on nitrites. Test results on nitrosamines in MEGGLE lactose monohydrate products are available. Results are given in the risk evaluation.

Conclusion: Neither the chemical composition nor the processing conditions indicate any possibility for nitrosamine contamination and formation in the process or storage of MEGGLE Products.

MEGGLE GmbH & Co. KG · Megglestr. 6-12 · 83512 Wasserburg am Inn, Deutschland · Telefon +49 (0) 8071 73-0 · Fax +49 (0) 8071 73-444 info@meggle.com · www.meggle.com · Rechtsform Kommanditgesellschaft · Sitz Wasserburg am Inn · Registergericht AG Traunstein HRA 7828 persönlich haftende Gesellschafterin: MEGGLE Group GmbH · Sitz Wasserburg am Inn · Registergericht AG Traunstein HRB 28495 Geschäftsführer: Matthias Oettel (Vorsitzender) · Henning Dehler · Marcus Hormuth USt-IdNr.: DE813497582 · St-Nr. 156/116/00043

INFORMATION Quality / Regulatory Affairs



EIP-1036

Revision 4

Date of issue: 03.05.2024

2/3

## **Nitrosamine Risk Evaluation**

1) Applicable category based on structure and origin of the excipient in support to evaluate the risk of formation of nitrosamines in the excipient <sup>1</sup>					
Target         Excipient:             Yes             Image: Proteins, enzymes, products of fermentation or extraction of biologic sources,	ineral acids or bases, ents, polymers, inorganic organic N-free entities,				
No fermentation or natural origin, organic solv					
No	Ye	s			
Chemical Synthetic Manufacturing Process? including processes to introduce chemically synthesized fragments to biological products or substances of natural origin					
<ul> <li>2) Is sodium nitrite (NaNO<sub>2</sub>) or any other nitrite or nitrosating agent<sup>2</sup>:</li> <li>used in any steps in the manufacturing process as reagents/catalyst?</li> <li>known to be used in the preparation of raw materials or intermediates used in the manufacturing process?</li> <li>known to be used in the preparation of reagents/catalysts/processing aids used in the manufacturing process?</li> </ul>	YES	NO ⊠ ⊠	Information not available		
<ul> <li>manufacturing process?</li> <li>known or likely to be generated as impurities during the manufacturing process?</li> <li>deliberately added to the process, including components of cell culture media or for fermentation?</li> </ul>					
<ul> <li>3) Have you analysed the excipient for:</li> <li>nitrites?</li> <li>nitrosamines?</li> <li>Nitrites: Method FIA; LoD 0.2 ppm / Nitrosamines NDMA, NDEA, NDPA, NDBA, NMOR, NPYR, NPIP: Method GC/TEA; LoQ 0.5 ppb / Tests conducted in a contracted laboratory.</li> </ul>	YES ⊠ ⊠	<b>NO</b>	<i>Test result</i> < LoD < LoQ		
<ul> <li>4) Is water used in the manufacturing process? If "Yes":</li> <li>i. is purified water<sup>3</sup> used in the manufacturing process?</li> <li>ii. if potable water is used, where possible, please report the maximum level of nitrite.</li> </ul>	YES ⊠ □ ⊠	NO □⊠□	Not applicable □		
Maximum levels of - Nitrites LoD 0.02 mg/l. Legal requirements according Directive (EU) 2020/2184: Nitrites < 0.5 mg/l	< LoD		Not available		
<ul> <li>5) Are there any secondary and/or tertiary amines<sup>4</sup> present in the manufacturing process as:</li> <li>raw material<sup>5</sup>?</li> <li>intermediate?</li> <li>reagent?</li> <li>processing aids?</li> <li>catalyst?</li> <li>solvent?</li> </ul>	YES	NO NANNAN	Not		
If yes, are those amines present in the - same - previous - subsequent step as any nitrosating agent mentioned in section 2?			applicable		

<sup>1</sup> Nitrogen-free materials are considered to be of lower inherent risk for nitrosamine contamination as they are typically manufactured and do not contain nitrosatable structures. Nitrosamines have been observed in medicinal products with N-containing APIs of chemical synthetic origin. EMA concludes that there is a very low risk of nitrosamines being present as impurities in biological medicinal products, although it can't be completely ruled out.
 <sup>2</sup> See Guidance 1 in Annex
 <sup>3</sup> Prepared by distillation, ion exchange, reverse osmosis
 <sup>4</sup> See Guidance 2 in Annex
 <sup>5</sup> 2020 IPEC General Glossary of Terms and Acronyms, https://www.ipec-europe.org/glossary.html

This MEGGLE Information was electronically released and is valid without signature.

MEGGLE GmbH & Co. KG · Megglestr. 6-12 · 83512 Wasserburg am Inn, Deutschland · Telefon +49 (0) 8071 73-0 · Fax +49 (0) 8071 73-444 info@meggle.com www.meggle.com Rechtsform Kommanditgesellschaft Sitz Wasserburg am Inn Registergericht AG Traunstein HRA 7828 persönlich haftende Gesellschafterin: MEGGLE Group GmbH · Sitz Wasserburg am Inn · Registergericht ÅG Traunstein HRB 28495 Geschäftsführer: Matthias Oettel (Vorsitzender) · Henning Dehler · Marcus Hormuth USt-IdNr.: DE813497582 · St-Nr. 156/116/00043

INFORMATION



3/3

Quality / Regulatory Affairs

EIP-1036

Revision 4

Date of issue: 03.05.2024

## **Nitrosamine Risk Evaluation**

6) Is there any amide, primary amine or ammonium salt used or present in the substance			
manufacturing process as:	YES	NO	
- Raw material?		$\square$	
- Intermediate?		$\boxtimes$	
- Reagent?		$\square$	
- Processing aids?		$\bowtie$	
- Catalyst?		$\bowtie$	
- Solvent?		$\boxtimes$	
- Washing Fluid?		$\bowtie$	
7) Recycled/recovered Solvents <sup>6</sup> :	YES	NO	
- Are recycled / recovered nitrogen containing solvents used in the manufacturing process?		$\boxtimes$	
			Not
8) Equipment:	YES	NO	applicable
<ul> <li>Is the substance produced in multipurpose equipment?</li> </ul>		$\boxtimes$	
- In case of multipurpose equipment, is the equipment used for manufacturing of any			
material involving nitrites, nitrosating agents or material with identified risk of formation of			$\boxtimes$
nitrosamines?			
- Are chloramines used as part of cleaning procedures used for manufacturing equipment?		$\bowtie$	
9) Additional comments, if any, not covered in the questionnaire			

#### Annex<sup>7</sup>:

### Guidance 1 (Sources of nitrosating agents)

Nitrosating agents to be considered include; nitrites (e.g. sodium nitrite, NaNO2) and nitrous acid (HNO2), nitric oxide (NO), nitrosyl halides (e.g. CINO, BrNO), dinitrogen trioxide (N2O3), dinitrogen tetroxide (N2O4) and organic nitrites (e.g. t-BuONO).

Other potential nitrosation risks:

- Side reaction in nitration reactions. Nitric acid typically contains nitric oxide as an impurity, additional nitrous acid may also be produced, leading to nitrosation, if any reducing agents are present.
- Hydroxylamine under oxidative conditions.
- Chloramines are known to generate N-nitrosamines under certain conditions and so should also be considered.<sup>8</sup>
- Ozone may lead to the formation of N-nitrosamines by initial oxidation of amines to nitrite.
- Use of azide salts and azide compounds is commonly followed by quenching with nitrous acid or nitrites and may lead to nitrite residues.
- Nitric acid and nitrates under reducing conditions may result in by-products with nitrosating activity.

This evaluation must include the use of all chemicals within a process, including those used during the guench and work-up as well as during reactive chemistry.

#### Guidance 2 (Sources of secondary and tertiary amines)<sup>9</sup>

Secondary amines are of greatest concern, however tertiary amines can also undergo nitrosation via more complex pathways. All secondary and tertiary aliphatic and aromatic amines should therefore be considered including those present as part of the starting material, intermediate or final structure as well as those introduced as reagents, catalysts, solvents or as impurities.

Tertiary amine bases (i.e. triethylamine, diisopropylethylamine and N-methylmorpholine) are known to degrade to secondary amines and have been implicated in N-nitrosamine formation.

Amines may also be introduced as impurities or degradants:

- Of common amide containing solvents such as N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMAC) and N-methylpyrrolidinone (NMP)
- Of quaternary ammonium salts such as tetrabutylammonium bromide (TBAB)
- Of primary amines such as monoethylamine
- Of starting materials, intermediates or the product itself

This evaluation must include the use of all chemicals within a process, including those used during the quench and work-up as well as during reactive chemistry.

### Guidance 3 (Potential contamination risks)

Consider all potential sources of contamination in input materials.

Use of recovered materials (solvents, reagents, catalysts) is of particular concern if appropriate controls are not put in place. The materials DMF, ortho-xylene and tributyltin chloride were highlighted by the EMA as materials at risk of cross contamination by N-nitrosamines. Sodium azide was highlighted by Health Canada for risk of cross contamination with nitrite.

Cross contamination from other processes using shared equipment should be considered. Steps performed under GMP (using solvents/reagents with appropriate controls, and controls on their recovery and reuse) are considered to be a lower cross contamination risk.

<sup>8</sup> Nawrocki, J et al. Nitrosamines and Water, J. Hazard. Mater. 2011, 189, 1-18.
<sup>9</sup> SCCS (Scientific Committee on Consumer Safety), Opinion on Nitrosamines and Secondary Amines in Cosmetic Products, 27 March 2012

This MEGGLE Information was electronically released and is valid without signature.

MEGGLE GmbH & Co. KG · Megglestr. 6-12 · 83512 Wasserburg am Inn, Deutschland · Telefon +49 (0) 8071 73-0 · Fax +49 (0) 8071 73-444 info@meggle.com · www.meggle.com · Rechtsform Kommanditgesellschaft · Sitz Wasserburg am Inn · Registergericht AG Traunstein HRA 7828 persönlich haftende Gesellschafterin: MEGGLE Group GmbH · Sitz Wasserburg am Inn · Registergericht ÅG Traunstein HRB 28495 Geschäftsführer: Matthias Oettel (Vorsitzender) · Henning Dehler · Marcus Hormuth USt-IdNr.: DE813497582 · St-Nr. 156/116/00043

<sup>&</sup>lt;sup>6</sup> See Guidance 3 in Annex

This information is partly transferred from the EFPIA decision tree for drug substances, published 1 Nov 2019